<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067920</url>
  </required_header>
  <id_info>
    <org_study_id>LIME01P2021</org_study_id>
    <nct_id>NCT05067920</nct_id>
  </id_info>
  <brief_title>Correlation Between Cycle Threshold (Ct) Values in COVID-19, Health Status and Laboratory Biomarkers in the Population of Medellin- Colombia Evaluated in a Specialized Laboratory.</brief_title>
  <official_title>Correlation Between Cycle Threshold (Ct) Values in RT-PCR - SARS-CoV-2, Health Status and Laboratory Biomarkers in the Population of Medellin- Colombia Evaluated in a Specialized Laboratory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Antioquia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratorio departamental de salud publica de Antioquia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sistema general de regalias (BPIN 2020000100152)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad de Antioquia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the correlation between the symptomaticity, Ct value, laboratory&#xD;
      biomarkers associated to COVID-19 and the disease progression in hospitalized patients and&#xD;
      outpatients with SARS-CoV2 infection diagnosed by RT-PCR assay for nasopharyngeal swab&#xD;
      specimens in a specialized laboratory at Medellin,Colombia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study, all patients giving written informed consent will&#xD;
      undergo a serial of test related to COVID-19. Rh and blood type will be obtained using the&#xD;
      Colombian ID card or official document.&#xD;
&#xD;
      All symptomatic and asymptomatic COVID19-positive patients will be evaluated for a period of&#xD;
      4 weeks at three different times of the study. In a single time, the mitochondrial DNA will&#xD;
      be measured, and the variability in the CT value, hemogram, cytokine levels, ratio of CD4 + /&#xD;
      CD8 + lymphocytes, levels of dehydrogenase lactate, ferritin and D-dimer, antibodies IgG and&#xD;
      IgM, will be measured on day 5, day 14 and day 28. In addition, spike S protein sequencing&#xD;
      and growing the virus in cell culture that meet specific criteria will be performed. A&#xD;
      physician will do clinical follow up through the period of the study for each patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Clinical immune response among COVID-19 patients related to CT value of rRT-PCR SARS-Cov-2</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
    <description>Calculated Ct value over 4 weeks, comparing the change in the immune status through the measurement of biomarkers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the duration of the positivity of the PCR test in asymptomatic and symptomatic patients through the follow-up</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate differences in the titers of immunoglobulins M and G against anti-RBD domain of the protein S in SARS-CoV2</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capacity of isolating the virus in cell culture with Ct&gt; 32 by PCR in COVID-19 patients</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of polymorphic variants or mutations in COVID-19 patients</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial DNA haplogroup relation in people infected with SARS CoV2</measure>
    <time_frame>Through study completion, an average of 4 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Asymptomatic patients</arm_group_label>
    <description>60 patients without COVID-19 symptoms related at the time of diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptomatic patients</arm_group_label>
    <description>60 patients with COVID-19 symptoms related at the time of diagnosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Levels of SARS-COV-2 antibodies</intervention_name>
    <description>Study of the SARS-COV-2 antibodies of COVID-19 IgM ( day 5th and 14th) and IgG ( day 14th and 28th)</description>
    <arm_group_label>Asymptomatic patients</arm_group_label>
    <arm_group_label>Symptomatic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>rRT-PCR SARS-Cov-2</intervention_name>
    <description>Real time RT-PCR for COVID-19 diagnosis at day 5th,14th and 28th</description>
    <arm_group_label>Asymptomatic patients</arm_group_label>
    <arm_group_label>Symptomatic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hematological and immunological biomarkers</intervention_name>
    <description>Laboratory data measure at day 5th,14th and 28th: Hemogram, cytokine levels, ratio of CD4 + / CD8 + lymphocytes, and levels of dehydrogenase lactate, ferritin, D-dimer.</description>
    <arm_group_label>Asymptomatic patients</arm_group_label>
    <arm_group_label>Symptomatic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Mitochondrial DNA</intervention_name>
    <description>One time quantification mitochondrial DNA haplogroup.</description>
    <arm_group_label>Asymptomatic patients</arm_group_label>
    <arm_group_label>Symptomatic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SARS-CoV-2 Viral Culturing</intervention_name>
    <description>Probability of isolating SARS-Cov-2 in cell culture related to CT value above 32.</description>
    <arm_group_label>Asymptomatic patients</arm_group_label>
    <arm_group_label>Symptomatic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sequencing COVID-19</intervention_name>
    <description>Sequencing viral protein spike (S) COVID-19 related to CT value below 15.</description>
    <arm_group_label>Asymptomatic patients</arm_group_label>
    <arm_group_label>Symptomatic patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COVID-19 confirmed patients with SARS-Cov-2 RT-PCR in Laboratorio Integrado de Medicina&#xD;
        Especializada (LIME) or IPS Universitaria Clinica Leon XIII&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  People under 18 years old.&#xD;
&#xD;
          -  Covid-19 diagnosis in the last seven days.&#xD;
&#xD;
          -  Specimen analyzed at LIME laboratory&#xD;
&#xD;
          -  Description of symptoms related to COVID-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunocompromised patients&#xD;
&#xD;
          -  Immunosuppressive treatments, chemotherapy or antiretroviral therapy&#xD;
&#xD;
          -  Outpatient anticoagulation therapy&#xD;
&#xD;
          -  Prior immunization for any vaccine in the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres F Zuluaga, MD, MSc, MeH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivone E Jimenez, PhD(c)</last_name>
    <phone>+57 (4) 2196022</phone>
    <email>ivone.jimenez@udea.edu.co</email>
  </overall_contact>
  <location>
    <facility>
      <name>Laboratorio Integrado de Medicina Especializada</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050022</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres F Zuluaga</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Antioquia</investigator_affiliation>
    <investigator_full_name>Andres Felipe Zuluaga Salazar</investigator_full_name>
    <investigator_title>Full profesor, senior researcher and head of the Department of Pharmacology and Toxicology in Antioquia University</investigator_title>
  </responsible_party>
  <keyword>Laboratory biomarkers</keyword>
  <keyword>Health condition</keyword>
  <keyword>CT value</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Mitochondrial DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

